Flexupp (previously Saturn)

We, as Saturn, developed an adjustable pessary, aimed at addressing the unmet need for effective treatment options for women with Pelvic Organ Prolapse (POP). POP affects half of women over the age of 40, causing symptoms that can seriously impact their quality of life. Current treatment options, such as surgery and generic pessaries, have limitations and complications. Saturn offers a personalized solution by providing a perfect fit and optimal support for each patient's complex, unique anatomy. Its adaptability ensures patient comfort and effectiveness, hence reducing side effects and treatment discontinuation.

The development of our product is based on extensive research and the expertise of the multidisciplinary team consisting of gynaecologists and engineers from Radboudumc and Zuyderland Medical Center. The patent for the technology and design is granted in 2020. The ongoing clinical study has shown positive results, with 100% successful fit and participants reporting comfort, symptom relief, and a desire to continue using our adjustable pessary. The potential market size of our pessary is significant. The global pessary market is expected to reach half a billion euros by 2028, with a potential patient population of 700 M women above the age of 40 years that suffer from POP worldwide. Our development plan involves obtaining certifications for initial market entry in the Netherlands followed by geographical expansion to Europe, the US, and worldwide. Revenue generation will primarily come from direct sales with a unit sale price of € 150.

The total revenue potential is € 22 M in 2030. At Saturn, we provide FemTech solutions for a large group of people suffering from pelvic floor disorders, significantly improving their quality of life and autonomy.